suratadenoturev

AXP000034.1 · Oncolytic virus

Platform
adenovirus (Ad5, hTERT promoter-driven E1A-IRES-E1B)
Originator
Oncolys BioPharma
Sponsor
Oncolys BioPharma

Names

NameTypeSource
suratadenoturevpreferred name, INNcurator, ncit
Telomelysinbrandncit
OBP-301codencit
Telomelycinsynonymncit

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5 (OBP-301)
Replication
conditionally replicating
Modifications
hTERT promoter drives E1A and E1B through an IRES
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C119617
FDA UNII
FV0JG1SX76

Approvals

No regulatory approval recorded.

Clinical trials (8)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06340711Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric AdenocarcinomaRecruitingPhase 22024-04-252028-0427Esophageal Adenocarcinoma; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
NCT04391049Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for SurgeryActive not recruitingPhase 12021-12-022024-10-0616Advanced Esophageal Adenocarcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8; Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage II Esophageal Adenocarcinoma AJCC v8; Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage III Esophageal Adenocarcinoma AJCC v8; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Squamous Cell Cancer; Squamous Cell Carcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma
NCT04685499Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive DiseaseTerminatedPhase 22021-05-032022-03-081Head and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease
NCT03921021Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric AdenocarcinomaCompletedPhase 22019-05-092023-06-2017Esophagogastric Adenocarcinoma
NCT03172819Special Combination of OBP-301 and PembrolizumabCompletedPhase 12017-10-012021-04-0622Advanced Solid Tumor
NCT03213054A Study of OBP-301 With Radiation Therapy in Patients With Esophageal CancerUnknownPhase 12017-07-072019-0312Esophageal Cancer
NCT03190824Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic MelanomaUnknownPhase 22016-12-222021-06-244Melanoma Stage III; Melanoma Stage Iv
NCT02293850Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular CarcinomaUnknownPhase 12014-102019-0418Carcinoma, Hepatocellular

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 37060176Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial.Molecular therapy : the journal of the American Society of Gene Therapy2023cited by trial NCT02293850
PMID 34153720Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments.European journal of cancer (Oxford, England : 1990)2021name in title: Telomelysin
PMID 19935775A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors.Molecular therapy : the journal of the American Society of Gene Therapy2010name in title: Telomelysin

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41315733p53-armed oncolytic adenovirus induces apoptosis in pancreatic cancer-associated stellate cells via macropinocytosis.Cancer gene therapy2026name in abstract: OBP-301
PMID 41469103P53-Armed Oncolytic Virotherapy Promotes the Efficacy of PD1 Blockade in Murine Osteosarcoma Tumors.Anticancer research2026name in abstract: OBP-301
PMID 41721933Turning pancreatic cancer from cold to hot: the promise of a p53-expressing oncolytic adenovirus (OBP-702).International journal of clinical oncology2026name in abstract: suratadenoturev
PMID 41895769P53-armed Oncolytic Adenovirus Enhances the Efficacy of PD-1 Blockade in Neuroblastoma by Inducing Immunogenic Cell Death.Anticancer research2026name in abstract: OBP-301
PMID 42005830Mitochondrial inhibition enhances the sensitivity of pancreatic ductal adenocarcinoma cells to oncolytic adenovirus.Molecular therapy. Oncology2026name in abstract: OBP-301
PMID 42269787NRG-GI007: Phase 1 Study of OBP-301, An Oncolytic Virus, and Definitive Chemoradiation in Locally Advanced Esophageal Cancer.International journal of radiation oncology, biology, physics2026name in title: OBP-301
PMID 42795690Virotherapy for Spinal and Spinal Cord Tumors: Current Evidence and Future Perspectives.Microorganisms2026name in abstract: OBP-301
PMID 41188286Serum extracellular vesicles containing adenoviral E1A-DNA as a predictive biomarker for liquid biopsy in oncolytic adenovirus therapy.Scientific reports2025name in abstract: OBP-301
PMID 38377118Fluorescence-guided assessment of bone and soft-tissue sarcomas for predicting the efficacy of telomerase-specific oncolytic adenovirus.PloS one2024name in abstract: OBP-301
PMID 38688833p53-Armed Oncolytic Virotherapy Improves Radiosensitivity in Soft-Tissue Sarcoma by Suppressing BCL-xL Expression.Acta medica Okayama2024name in abstract: OBP-301
PMID 39108499p53-armed oncolytic virotherapy induces abscopal effect in osteosarcoma by promoting immunogenic cell death.Molecular therapy. Oncology2024name in abstract: OBP-301
PMID 39499326Dendritic cell maturation is induced by p53-armed oncolytic adenovirus via tumor-derived exosomes enhancing systemic antitumor immunity.Cancer immunology, immunotherapy : CII2024name in abstract: OBP-301
PMID 36669725Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma.Cancer letters2023name in abstract: Telomelysin
PMID 37972012p53-armed oncolytic adenovirus induces autophagy and apoptosis in KRAS and BRAF-mutant colorectal cancer cells.PloS one2023name in abstract: OBP-301
PMID 35503449Overexpression of Adenovirus E1A Reverses Transforming Growth Factor-β-induced Epithelial-mesenchymal Transition in Human Esophageal Cancer Cells.Acta medica Okayama2022name in abstract: OBP-301
PMID 35681700Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options.Cancers2022name in abstract: Telomelysin
PMID 36281608[Telomerase-Specific Oncolytic Adenovirus Expressing p53 Gene Stimulating CD8+ Memory T Cells in Pancreatic Cancer].Gan to kagaku ryoho. Cancer & chemotherapy2022name in abstract: OBP-301
PMID 36381653An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma.Molecular therapy oncolytics2022name in abstract: suratadenoturev
PMID 33477279Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment.International journal of molecular sciences2021name in abstract: OBP-301
PMID 33886686Oncolytic virotherapy promotes radiosensitivity in soft tissue sarcoma by suppressing anti-apoptotic MCL1 expression.PloS one2021name in abstract: OBP-301
PMID 34023506Local oncolytic adenovirotherapy produces an abscopal effect via tumor-derived extracellular vesicles.Molecular therapy : the journal of the American Society of Gene Therapy2021name in abstract: Telomelysin
PMID 34277838Current status of intralesional agents in treatment of malignant melanoma.Annals of translational medicine2021name in abstract: Telomelysin
PMID 31991110Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.Molecular therapy : the journal of the American Society of Gene Therapy2020name in abstract: Telomelysin
PMID 32085583Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy.Cancers2020name in abstract: Telomelysin
PMID 32322667Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer.Molecular therapy oncolytics2020name in abstract: OBP-301
PMID 32637577Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression.Molecular therapy oncolytics2020name in abstract: OBP-301
PMID 30462296Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.Japanese journal of clinical oncology2019name in abstract: Telomelysin
PMID 31346579Multidisciplinary oncolytic virotherapy for gastrointestinal cancer.Annals of gastroenterological surgery2019name in abstract: Telomelysin
PMID 30270333A Flow Cytometry-Based Method to Determine the Titer of Adenoviruses Expressing an Extraneous Gene.Biological & pharmaceutical bulletin2018name in abstract: OBP-301
PMID 27171483Therapeutic Cell-Cycle-Decoy Efficacy of a Telomerase-Dependent Adenovirus in an Orthotopic Model of Chemotherapy-Resistant Human Stomach Carcinomatosis Peritonitis Visualized With FUCCI Imaging.Journal of cellular biochemistry2017name in abstract: OBP-301
PMID 28685948Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.Cancer science2017name in abstract: OBP-301
PMID 27356624Ablation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas.Scientific reports2016name in abstract: Telomelysin
PMID 27673332Efficacy of a Cell-Cycle Decoying Killer Adenovirus on 3-D Gelfoam®-Histoculture and Tumor-Sphere Models of Chemo-Resistant Stomach Carcinomatosis Visualized by FUCCI Imaging.PloS one2016name in abstract: OBP-301
PMID 26033451Targeting tumors with a killer-reporter adenovirus for curative fluorescence-guided surgery of soft-tissue sarcoma.Oncotarget2015name in abstract: OBP-301
PMID 23728900Telomerase-specific oncolytic adenovirus: antitumor effects on radiation-resistant head and neck squamous cell carcinoma cells.Head & neck2014name in abstract: OBP-301
PMID 22886913Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice.International journal of cancer2013name in abstract: Telomelysin
PMID 23315976Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells.Molecular cancer therapeutics2013name in abstract: OBP-301
PMID 23718223Telomelysin shows potent antitumor activity through apoptotic and non-apoptotic cell death in soft tissue sarcoma cells.Cancer science2013name in title: Telomelysin
PMID 23863576[Current state of oncolytic virotherapy in Japan].Gan to kagaku ryoho. Cancer & chemotherapy2013name in abstract: OBP-301
PMID 24065118Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines.Oncology reports2013name in abstract: Telomelysin
PMID 24081978A genetically engineered oncolytic adenovirus decoys and lethally traps quiescent cancer stem-like cells in S/G2/M phases.Clinical cancer research : an official journal of the American Association for Cancer Research2013name in abstract: OBP-301
PMID 24356717Oncolytic adenovirus-induced autophagy: tumor-suppressive effect and molecular basis.Acta medica Okayama2013name in abstract: OBP-301
PMID 21740362Synergistic interaction of telomerase-specific oncolytic virotherapy and chemotherapeutic agents for human cancer.Current pharmaceutical biotechnology2012name in abstract: Telomelysin
PMID 22244827A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.European journal of cancer (Oxford, England : 1990)2012name in abstract: OBP-301
PMID 22525466Ataxia-telangiectasia mutated and the Mre11-Rad50-NBS1 complex: promising targets for radiosensitization.Acta medica Okayama2012name in abstract: Telomelysin
PMID 22720091The hTERT promoter enhances the antitumor activity of an oncolytic adenovirus under a hypoxic microenvironment.PloS one2012name in abstract: Telomelysin
PMID 22956040Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.Cancer gene therapy2012name in abstract: Telomelysin
PMID 21193997Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus.Journal of cancer research and clinical oncology2011name in abstract: Telomelysin
PMID 21325287Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas.Clinical cancer research : an official journal of the American Association for Cancer Research2011name in abstract: OBP-301
PMID 21362583Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines.Auris, nasus, larynx2011name in title: Telomelysin
PMID 21504319Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer.Expert review of anticancer therapy2011name in abstract: OBP-301
PMID 21709712A novel molecular therapy using bioengineered adenovirus for human gastrointestinal cancer.Acta medica Okayama2011name in abstract: Telomelysin
PMID 19662088Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.Cancer gene therapy2010name in abstract: Telomelysin
PMID 19935710A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy.Oncogene2010name in abstract: OBP-301
PMID 20043095Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma.Oncology reports2010name in title: Telomelysin
PMID 20168351Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma.Cancer gene therapy2010name in title: OBP-301
PMID 20485131In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy.Annals of surgery2010name in abstract: Telomelysin
PMID 20501801Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer.Molecular cancer therapeutics2010name in abstract: Telomelysin
PMID 21045143Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery.Cancer research2010name in abstract: Telomelysin
PMID 18754077Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin).Investigational new drugs2009name in title: Telomelysin
PMID 19139126Telomerase-specific virotherapy in an animal model of human head and neck cancer.Molecular cancer therapeutics2009name in abstract: Telomelysin
PMID 19155526A novel antiangiogenic effect for telomerase-specific virotherapy through host immune system.Journal of immunology (Baltimore, Md. : 1950)2009name in abstract: Telomelysin
PMID 19216621Telomerase-specific virotherapy for human squamous cell carcinoma.Expert opinion on biological therapy2009name in abstract: Telomelysin
PMID 19318473Telomerase-specific virotheranostics for human head and neck cancer.Clinical cancer research : an official journal of the American Association for Cancer Research2009name in abstract: OBP-301
PMID 19372571Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer.Molecular cancer therapeutics2009name in abstract: Telomelysin
PMID 19461167[Oncolytic virotherapy for human solid tumors].Gan to kagaku ryoho. Cancer & chemotherapy2009name in abstract: Telomelysin
PMID 19787218Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer.Oncology reports2009name in title: Telomelysin
PMID 19798455Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2009name in abstract: OBP-301
PMID 19887549Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses.Molecular cancer therapeutics2009name in abstract: Telomelysin
PMID 17981675Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents.Frontiers in bioscience : a journal and virtual library2008name in abstract: Telomelysin
PMID 17982491Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation.Oncogene2008name in abstract: Telomelysin
PMID 18274558Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model.Cancer gene therapy2008name in title: OBP-301
PMID 18338751Combination of oncolytic adenovirotherapy and Bax gene therapy in human cancer xenografted models. Potential merits and hurdles for combination therapy.International journal of cancer2008name in abstract: Telomelysin
PMID 18580968Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells.Gene therapy2008name in abstract: OBP-301
PMID 18754863Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers.Cancer science2008name in abstract: Telomelysin
PMID 19020715Anti-tumor effects of telomelysin for head and neck squamous cell carcinoma.Oncology reports2008name in title: Telomelysin
PMID 19122384Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.Uirusu2008name in abstract: Telomelysin
PMID 17346111Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.Current cancer drug targets2007name in abstract: Telomelysin
PMID 17926546[Theranostic application of telomerase-specific oncolytic adenovirus for human cancer].Nihon rinsho. Japanese journal of clinical medicine2007name in abstract: Telomelysin
PMID 16356494Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.Experimental cell research2006name in title: OBP-301
PMID 16477640Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy.International journal of cancer2006name in abstract: Telomelysin
PMID 15735729Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').Oncogene2005name in title: Telomelysin
PMID 15342413Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene.Cancer research2004name in abstract: Telomelysin

Notes

Telomelysin/OBP-301. Telomerase (hTERT) promoter drives E1A and E1B via an IRES. Partnered with Chugai (Japan) and with Merck/Roche in combination studies at various times; partnership history not re-verified.

How to cite

suratadenoturev (AXP000034.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000034.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.